Critical periods for chlorpyrifos-induced developmental neurotoxicity: alterations in adenylyl cyclase signaling in adult rat brain regions after gestational or neonatal exposure. by Meyer, Armando et al.
The ability of organophosphate insecticides
such as chlorpyrifos (CPF) to elicit develop-
mental neurotoxicity has received a great deal
of attention in the last decade (Barone et al.
2000; Landrigan 2001; Landrigan et al. 1999;
May 2000; Physicians for Social Responsibility
1995; Pope 1999; Rice and Barone 2000;
Slotkin 1999, in press b), resulting in its
restricted domestic use [U.S. Environmental
Protection Agency (EPA) 2000a, 2000b,
2001]. It is now evident that CPF alters brain
development by a panoply of mechanisms in
addition to cholinesterase inhibition (Barone
et al. 2000; Das and Barone 1999; Pope 1999;
Schuh et al. 2002; Slotkin 1999, in press b),
compromising neural cell replication and dif-
ferentiation, axonogenesis and synaptogenesis,
and the programming of synaptic function
(Buznikov et al. 2001; Crumpton et al. 2000;
Dam et al. 1998, 1999a, 1999b; Garcia et al.
2001; Howard and Pope 2002; Huff et al.
2001; Johnson et al. 1998; Liu et al. 2002;
Whitney et al. 1995; Yanai et al. 2002; Zhang
et al. 2002). One prominent mechanism by
which CPF acts on the developing brain is
through its ability to alter the expression and
function of cell-signaling proteins that control
the generation of cyclic AMP (cAMP)
(Crumpton et al. 2000; Garcia et al. 2001;
Meyer et al. 2003; Olivier et al. 2001; Schuh
et al. 2002; Song et al. 1997; Zhang et al.
2002). In turn, cAMP coordinates the critical
transition from cell replication to cell differen-
tiation (Bhat et al. 1983; Claycomb 1976;
Guidotti 1972; Hultgårdh-Nilsson et al. 1994;
Van Wijk et al. 1973) and, during brain devel-
opment, plays a pivotal role in axonal out-
growth, neural plasticity, and apoptosis
(Shaywitz and Greenberg 1999; Stachowiak
et al. 2003). We recently demonstrated that,
during critical developmental periods, CPF
alters the activity of adenylyl cyclase (AC), the
enzyme responsible for cAMP production, as
well as the G-proteins that couple neurotrans-
mitter receptors to AC, along with the recep-
tor-mediated responses to neurotransmitters
that serve neurotrophic roles in brain develop-
ment (Aldridge et al. 2003; Garcia et al. 2001;
Meyer et al. 2003; Song et al. 1997).
The question remains as to whether the
ability of CPF to alter cell signaling lasts into
adulthood, or instead, whether the effects are
restricted to developmental stages in which
these signals affect neural cell differentiation.
Certainly, CPF exposure leads to behavioral
anomalies that emerge in adolescence and per-
sist in adults (Levin et al. 2001, 2002;
Richardson and Chambers 2003; Slotkin et al.
2001a, 2002). In association with the behav-
ioral deficits, developmental CPF exposure
evokes profound alterations in activity of neu-
rotransmitter systems that operate through
AC, notably cholinergic and catecholaminergic
pathways (Qiao et al. 2003; Slotkin, in press a;
Slotkin et al. 2001a, 2002). In the present
study, we investigated the long-term impact of
gestational or neonatal CPF exposure on the
functioning of the AC signaling cascade,
focusing on four different critical windows:
the formation of the neural tube [gestational
days (GD) 9–12], the late gestational period
(GD17–20) in which sexual differentiation of
the brain is initiated (McCarthy 1994; Mong
and McCarthy 1999), and postnatal phases of
terminal neuronal differentiation and synapto-
genesis [postnatal days (PN) 1–4, PN11–14];
these are the same treatment windows exam-
ined for short-term effects in our previous
study (Meyer et al. 2003). Doses were chosen
to enable us to determine whether the thresh-
old for effects on AC signaling lies below that
for systemic toxicity and/or inhibition of
cholinesterase (Aldridge et al. 2003; Garcia
et al. 2003; Meyer et al. 2003; Qiao et al.
2002; Slotkin 1999, in press a).
In adulthood (PN60), we examined the
effects of CPF on AC in several ways. First, we
evaluated basal enzymatic activity. Second, we
determined the response to two AC stimu-
lants, forskolin and Mn2+. Because the two
stimulants act at different epitopes on the AC
molecule, the preference for one over the other
reﬂects shifts in molecular conformation, pri-
marily inﬂuenced by the AC isoform (Zeiders
et al. 1999). Third, we probed the AC
response to speciﬁc receptor-mediated activa-
tion with isoproterenol, a β-adrenoceptor
(βAR) agonist linked to AC by the stimulatory
G-protein (Gs). This receptor has deﬁned neu-
rotrophic roles in brain cell development and is
a postulated target for CPF (Auman et al.
2000; Dreyfus 1998; Garcia et al. 2001;
Kasamatsu 1985; Kulkarni et al. 2002; Kwon
et al. 1996; Morris et al. 1983; Popovik and
Environmental Health Perspectives • VOLUME 112 | NUMBER 3 | March 2004 295
Address correspondence to T.A. Slotkin, Box 3813
DUMC, Department of Pharmacology and Cancer
Biology, Duke University Medical Center, Durham,
NC 27710 USA. Telephone: (919) 681-8015. Fax:
(919) 684-8197. E-mail: t.slotkin@duke.edu
This work was supported by grants ES10387 and
ES10356 from the U.S. Public Health Service and
by Conselho Nacional de Pesquisa – CNPq/Brazil.
The authors declare they have no competing ﬁnancial
interests.
Received 22 September 2003; accepted 24 November
2003.
Critical Periods for Chlorpyrifos-Induced Developmental Neurotoxicity:
Alterations in Adenylyl Cyclase Signaling in Adult Rat Brain Regions 
after Gestational or Neonatal Exposure
Armando Meyer,1 Frederic J. Seidler,2 Justin E. Aldridge,2 Charlotte A. Tate,2 Mandy M. Cousins,2 and 
Theodore A. Slotkin2
1Centro de Estudos da Saúde do Trabalhador e Ecologia Humana, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de
Janeiro, Brazil; 2Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA
Developmental exposure to chlorpyrifos (CPF) alters the function of a wide variety of neural systems.
In the present study we evaluated the effects in adulthood of CPF exposure of rats during different
developmental windows, using the adenylyl cyclase (AC) signaling cascade, which mediates the cel-
lular responses to numerous neurotransmitters. Animals were exposed on gestational days (GD)
9–12 or 17–20 or on postnatal days (PN) 1–4 or 11–14 and assessed at PN60. In addition to basal
AC activity, we evaluated the responses to direct AC stimulants (forskolin, Mn2+) and to isopro-
terenol, which activates signaling through β-adrenoceptors coupled to stimulatory G-proteins. CPF
exposure in any of the four periods elicited signiﬁcant changes in AC signaling in a wide variety of
brain regions in adulthood. In general, GD9–12 was the least sensitive stage, requiring doses above
the threshold for impaired maternal weight gain, whereas effects were obtained at subtoxic doses
for all other regimens. Most of the effects were heterologous, involving signaling elements down-
stream from the receptors, and thus shared by multiple stimulants; superimposed on this basic pat-
tern, there were also selective alterations in receptor-mediated responses, in G-protein function, and in
AC expression and subtypes. Exposures conducted at GD17–20 and later all produced sex-selective
alterations. These results suggest that developmental exposure to CPF elicits long-lasting alterations
in cell-signaling cascades that are shared by multiple neurotransmitter and hormonal inputs; the
resultant abnormalities of synaptic communication are thus likely to occur in widespread neural cir-
cuits and their corresponding behaviors. Key words: adenylyl cyclase, β-adrenoceptor, brain devel-
opment, chlorpyrifos, organophosphate insecticides. Environ Health Perspect 112:295–301 (2004).
doi:10.1289/ehp.6755 available via http://dx.doi.org/ [Online 24 November 2003]
Research ArticleHaynes 2000; Schwartz and Nishiyama 1994;
Slotkin et al. 1989; Song et al. 1997). Our
studies also characterized the regional speci-
ﬁcity and sex selectivity of the long-term effects
of CPF on cell signaling.
Materials and Methods
Animal treatments. All experiments using live
animals were carried out in accordance with
the Declaration of Helsinki (World Medical
Association 2002) and with the Guide for the
Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources 1996) as
adopted and promulgated by the National
Institutes of Health. Timed pregnant Sprague-
Dawley rats were housed in breeding cages,
with a 12-hr light/dark cycle and with free
access to food and water. CPF was dissolved in
DMSO to provide rapid and complete absorp-
tion (Whitney et al. 1995) and was injected
subcutaneously in a volume of 1 mL/kg body
weight; control animals received vehicle
(DMSO) injections on the same schedules.
For exposure on GD9–12 or GD17–20, dams
were injected daily with CPF at 1 or 5 mg/kg
body weight. These doses span the threshold
for inhibition of fetal brain cholinesterase
activity, fetal growth impairment, and
reduced maternal weight gain, all of which
become evident at ≥ 5 mg/kg (Garcia et al.
2003; Qiao et al. 2002). On the day of birth,
all pups were randomized within their respec-
tive treatment groups and redistributed to the
dams with a litter size of 10 to maintain a
standard nutritional status. Randomization
was repeated at intervals of several days; in
addition, dams were rotated among litters to
distribute any maternal caretaking differences
randomly across litters and treatment groups.
Animals were weaned on PN21. On PN60,
animals were decapitated and the brain was
dissected into cerebral cortex, hippocampus,
striatum, midbrain, brainstem, and cerebel-
lum, which were frozen with liquid nitrogen
and stored at –45°C.
For studies of CPF effects in the ﬁrst few
days after birth, animals were given 1 mg/kg
by subcutaneous injection daily on PN1–4;
for studies in older animals, which tolerate
higher doses (Campbell et al. 1997; Pope and
Chakraborti 1992; Pope et al. 1991; Whitney
et al. 1995), daily treatment with 5 mg/kg was
given on PN11–14. The same randomization
procedure was followed. Neither regimen
evokes weight loss or mortality (Campbell
et al. 1997; Dam et al. 1998; Johnson et al.
1998; Song et al. 1997), and in the present
study we did not observe any changes in suck-
ling or maternal caretaking. Samples were
obtained on PN60 as described above.
None of the prenatal or postnatal treat-
ment regimens evoked a signiﬁcant change in
weight of any of the brain regions on PN60,
nor were there any deficits in body weight
(data not shown).
Membrane preparation and assays. All of
the assay methodologies used in this study have
been described previously (Aldridge et al.
2003; Auman et al. 2000, 2001; Meyer et al.
2003; Slotkin et al. 2001b; Zeiders et al. 1997,
1999), so only brief descriptions are provided
here. Tissues were thawed and homogenized
with a Polytron (Brinkmann Instruments,
Westbury, NY), and cell membranes were pre-
pared and washed by sequential sedimentation
at 40,000 × g. The membrane pellets were dis-
persed with a smooth-glass homogenizer and
used for ligand binding and AC assays.
[125I]Iodopindolol (67 pM) was used to deter-
mine βAR binding, and nonspecific binding
was assessed by displacement with 100 µM iso-
proterenol. AC activity was determined by
enzymatic generation of cAMP, which was
then measured by radioimmunoassay. In addi-
tion to measuring basal AC activity, we
assessed the response to βAR stimulation
(100 µM isoproterenol), as well as the response
to the direct AC stimulants forskolin (100 µM)
and Mn2+ (10 mM). These concentrations of
each stimulant produce maximal responses, as
assessed in previous studies (Auman et al.
2000, 2001; Slotkin et al. 2001b; Zeiders et al.
1997, 1999).
Data analysis. Data are presented as means
and SEs obtained from eight animals of each
sex for each prenatal treatment group and six
animals per sex for each postnatal treatment
group. For convenience, results are given as
the percent change from control values, but
statistical evaluations were always conducted
on the original data. To establish treatment
differences in receptor binding or AC activity,
a global analysis of variance (ANOVA; data
log transformed whenever variance was het-
erogeneous) was ﬁrst conducted across the in
vivo treatment groups, sexes, regions, and
measurements made on the membranes (βAR
binding, AC activity under four different con-
ditions); the latter were considered to be
repeated measures because each membrane
preparation was used for the multiple condi-
tions under which AC was determined. As
justified by significant interactions of treat-
ment with the other variables, data were then
subdivided to permit testing of individual
treatments and AC measures that differed
from control values; these were conducted by
lower-order ANOVAs, followed, where
appropriate, by Fisher’s protected least signiﬁ-
cant difference to identify individual values
for which the CPF groups differed from the
corresponding control. For all tests, signifi-
cance for main treatment effects was assumed
at p < 0.05; however, for interactions at
p < 0.1, we also examined whether lower-
order main effects were detectable after subdi-
vision of the interactive variables (Snedecor
and Cochran 1967).
For presentation, control values (Table 1)
were combined across the multiple cohorts
(controls used for administration on GD9–12,
GD17–20, PN1–4, PN11–14). However, sta-
tistical comparisons of the effects of CPF were
made only with the appropriately matched
control cohort.
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Table 1. Binding parameters and AC levels in controls.
Measure, sex Cerebral cortex Hippocampus Striatum Midbrain Brainstem Cerebellum
βAR binding (fmol/mg protein)
Male 39.9 ± 0.9 17.3 ± 0.7 44.1 ± 1.0 15.8 ± 0.3 10.0 ± 0.3 27.2 ± 0.6
Female 41.4 ± 0.9 18.1 ± 0.7 46.3 ± 1.6 16.6 ± 0.3 10.2 ± 0.3 27.1 ± 0.7
Basal AC (pmol/min/mg protein)
Male 177 ± 11 146 ± 6 141 ± 6 240 ± 9 147 ± 9 267 ± 12
Female 186 ± 10 142 ± 4 137± 7 242 ± 10 133 ± 7 248 ± 12
Isoproterenol-stimulated AC (pmol/min/mg protein)
Male 197 ± 12 153 ± 6 151 ± 6 254 ± 9 153 ± 8 328 ± 14
Female 208 ± 12 148 ± 5 153 ± 8 250 ± 10 141 ± 7 301 ± 12
Forskolin-stimulated AC (pmol/min/mg protein)
Male 1,206 ± 93 576 ± 27 3,817 ± 194 1,040 ± 51 421 ± 14 997 ± 40
Female 1,340 ± 113 594 ± 21 3,960 ± 199 1,049 ± 41 428 ± 15 1,019 ± 47
Mn2+-stimulated AC (pmol/min/mg protein)
Male 1,811 ± 119 1,174 ± 60 2,145 ± 72 1,485 ± 60 828 ± 24 1,932 ± 94
Female 2,007 ± 135 1,184 ± 42 2,292 ± 98 1,481 ± 66 817 ± 28 2,015 ± 106
Values were combined across multiple cohorts (controls used for CPF administration on GD9–12, GD17–20, PN1–4, and PN11–14). However, statistical comparisons of the effects of CPF
were made only with the appropriately matched control cohort. None of the sex differences is statistically signiﬁcant.Materials. Animals were purchased from
Zivic Laboratories (Pittsburgh, PA, USA).
CPF was purchased from Chem Service (West
Chester, PA, USA). [125I]Iodopindolol (spe-
cific activity, 2,200 Ci/mmol) was obtained
from Perkin-Elmer Life Sciences (Boston,
MA, USA), and cAMP radioimmunoassay kits
were purchased from Amersham Biosciences
(Piscataway, NJ, USA). All other chemicals
were purchased from Sigma Chemical Co. (St.
Louis, MO, USA).
Results
CPF exposure on GD9–12. CPF administra-
tion during the neural tube stage had no long-
term effects on βAR binding in any of the
brain regions (Figure 1A). In contrast, there
were significant effects on AC activity that
depended on the type of AC measurement
(significant interaction of treatment × meas-
ure). Examining this effect for each dose
group, it was apparent that the alterations
were confined to those receiving 5 mg/kg
(p < 0.0002; not significant for 1 mg/kg
group). Because the statistics could not distin-
guish significant selectivity for sex or brain
region (i.e., no interaction of treatment × sex
or treatment × region), we characterized the
differential effect on AC measures by calculat-
ing the speciﬁc changes elicited by each stimu-
lant, namely, the ratio of activity with the
added stimulant to basal AC (Figure 1B). CPF
exposure elicited small but signiﬁcant increases
in the response to isoproterenol, forskolin, and
Mn2+. Additionally, the effect on the iso-
proterenol response was significantly smaller
than that for forskolin (p < 0.03). There was no
change in the forskolin:Mn2+ activity ratio (data
not shown). In light of the positive findings
with this ﬁrst treatment regimen, the scope of
the regions examined was extended to include
hippocampus and striatum for the subsequent
studies.
CPF exposure on GD17–20. In contrast to
the effects of GD9–12 CPF exposure, shifting
the exposure period to later in gestation had a
profound, sex-dependent effect on βAR bind-
ing in adulthood. Overall, ANOVA identiﬁed
treatment interactions with sex and brain
region: p < 0.006 for treatment × sex, p < 0.02
for treatment × region, p < 0.02 for treatment
× sex × region. Furthermore, the effects were
distinguishable both at the low dose (1 mg/kg)
of CPF (p < 0.002 for treatment × sex) as well
as at the higher (5 mg/kg) dose (p < 0.03,
p < 0.004, p < 0.004, for the three interac-
tions, respectively). In light of the consistent
sex differences, we subdivided the data into
males and females for presentation and further
analysis (Figure 2). Males showed a treatment
× region interaction, reﬂecting small elevations
in the striatum and midbrain, as well as a
reduction in the cerebellum in the high-dose
group. In contrast, females showed signiﬁcant
overall reductions (main treatment effect) that
were robustly signiﬁcant even with the lower
dose of CPF (p < 0.02 across all regions). The
largest individual changes were obtained for
the striatum and brainstem.
CPF exposure on GD17–20 also influ-
enced AC measures in a fashion that interacted
with brain region (treatment × region × mea-
sure, p <0 .1), so values were subdivided into
the individual regions and reexamined for
treatment effects and interactions. CPF effects
were identified in the hippocampus (main
treatment effect, p < 0.05), striatum (treatment
× measure, p < 0.02; treatment × sex, p < 0.1),
midbrain (treatment × sex, p < 0.1), and cere-
bellum (treatment × sex, p < 0.07), and these
are displayed in Figure 3; results for the other
regions are not shown. For the hippocampus,
CPF treatment evoked an overall elevation of
AC, without preferential effects on any of the
stimulants (Figure 3A); effects were signiﬁcant
only at 5 mg/kg. In the striatum, there was a
sex disparity, with males tending to show
increases in AC and females showing decreases.
For individual measures, males exposed to
5 mg/kg CPF showed signiﬁcant elevations in
the responses to the two direct AC stimulants
forskolin and Mn2+, but the isoproterenol
response was unaffected. In the midbrain, CPF
exposure similarly tended to elevate AC in a
sex-selective manner (treatment × sex interac-
tion), but considered separately, neither sex
passed the threshold for statistically signiﬁcant
differences (Figure 3C); the sex difference
reflected the relatively greater effect of the
lower dose of CPF in males compared with
that in females. In the cerebellum, CPF expo-
sure had a preferential effect on AC in females,
evoking significant elevations at either 1 or
5 mg/kg (Figure 3D); the effects were exerted
across all AC measures, without preference for
different stimulants. Males did not show any
signiﬁcant differences.
CPF exposure on PN1–4. In contrast to
the effects of GD17–20 exposure, shifting the
period of CPF treatment to the early neonatal
period resulted in no significant long-term
alterations of βAR binding on PN60 (data not
shown). However, there was a signiﬁcant over-
all elevation of AC (main treatment effect,
p < 0.05) that again depended on sex, brain
region, and AC measure (p < 0.03 for treat-
ment × sex, p < 0.03 for treatment × measure,
p < 0.07 for treatment × sex × measure,
p < 0.009 for treatment × region × measure).
Accordingly, we performed lower-order assess-
ments on each region, looking for main treat-
ment effects and interactions of treatment
Article | Developmental neurotoxicity of chlorpyrifos
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Figure 1. Effects of GD9–12 CPF exposure on PN60 (A) βAR binding and AC activity (ANOVA for Rx × measure,
p < 0.002) and (B) AC activity ratios. Abbreviations: Bs, brainstem; Cb, cerebellum; Cx, cerebral cortex; Fsk,
forskolin; Iso, isoproterenol; Mb, midbrain; NS, not signiﬁcant; Rx, treatment. Data are means and SEs of the
percent change from corresponding control values (Table 1). Although effects on βAR binding were not sig-
niﬁcant, ANOVA indicated a signiﬁcant treatment effect that depended on the speciﬁc AC measure, and the
effects were restricted to the group exposed to 5 mg/kg CPF. To characterize the differential effects on AC
measures, activity ratios were calculated relative to basal AC activity (B). ANOVAs for each measure are
shown within the ﬁgure. Separate statistical evaluations for males and females or for each region were not
carried out because of the absence of treatment interactions with these variables. 
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Figure 2. Effects of GD17–20 CPF exposure on PN60
βAR binding. Abbreviations: Bs, brainstem; Cb, cere-
bellum; Cx, cerebral cortex; Hp, hippocampus; Mb,
midbrain; Rx, treatment; St, striatum. Data are
means and SEs of the percent change from corre-
sponding control values (Table 1). Across all treat-
ments, all regions, and both sexes, ANOVA indicated
a signiﬁcant treatment effect that differed between
the two sexes (Rx × sex, p < 0.006; Rx × region,
p < 0.02; Rx × sex × region, p < 0.02), so values were
separated for males and females. Lower-order
ANOVAs for each sex appear within the ﬁgure.
*Individual groups differ signiﬁcantly from the control.
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Rx × region, p < 0.005with other variables. Two of the regions that
were targeted by GD17–20 exposure, the hip-
pocampus and striatum, showed no signiﬁcant
overall effects on AC with the PN1–4 regimen
(data not shown). The cerebral cortex and
brainstem each showed a signiﬁcant treatment
× measure interaction without sex selectivity
(no treatment × sex interaction), so results for
males and females were combined for presen-
tation (Figure 4A). Both regions showed sig-
nificant elevations of AC but with different
preference for the various stimulants. In the
cerebral cortex, signiﬁcant elevations were seen
for direct AC stimulants (forskolin, Mn2+),
whereas in the brainstem, the effects were
preferential for isoproterenol. Unlike the other
two regions, there were sex-selective effects in
the cerebellum, necessitating separate analysis
of males and females (Figure 4B). Males dis-
played signiﬁcant deﬁcits in basal and isopro-
terenol-stimulated AC activity, whereas
females showed a global elevation of AC.
CPF exposure on PN11–14. With this
treatment regimen, βAR binding showed sig-
nificant overall decreases (main treatment
effect, p < 0.03) that were distinctly sex selec-
tive (treatment × sex, p < 0.03). Separating the
values for males and females indicated a small
but consistent decrement in females but not
males (Figure 5). Similarly, AC activities in
this treatment group did not indicate region-
ally selective CPF effects but did indicate the
need to examine males and females separately
for differential effects on the various AC mea-
sures (treatment × measure, p < 0.07; treat-
ment × sex × measure, p < 0.002). In males,
CPF treatment evoked significant, 10–20%
decrements in basal and isoproterenol-stimu-
lated AC activity with relatively smaller effects
on the responses to forskolin and Mn2+
(Figure 6A). Females showed a more uniform
pattern, with a significant overall decrease
(main effect of CPF) and speciﬁc reductions
in basal and forskolin-stimulated activity
(Figure 6B); the cerebral cortex showed the
greatest overall effect and was the only region
in which the reductions achieved statistical sig-
nificance individually (p < 0.02). Again, to
characterize the differences in the effects of
CPF directed toward speciﬁc AC stimulants,
we calculated AC activity ratios (Figure 6C).
In males, the response to isoproterenol was
suppressed relative to that to forskolin, with
signiﬁcant deﬁcits in striatum and cerebellum.
In contrast, the same measurement in females
indicated overall increases. Additionally,
females showed a signiﬁcant reduction in the
forskolin:Mn2+ AC activity ratio.
Discussion
Results of the present study indicate that expo-
sure to CPF during development elicits long-
term alterations in AC-mediated cell signaling
in the central nervous system, with differential
effects according to sex and brain region that
depend upon the exposure period. This effec-
tively rules out the possibility that CPF simply
interacts directly with the neurotransmitter
receptors or proteins of the AC signaling cas-
cade (Huff and Abou-Donia 1995; Huff et al.
1994; Ward and Mundy 1996), in which case
the alterations would have been similar in every
region, for both sexes, and for each regimen.
Instead, our ﬁndings point to disruption of the
program for development of cell signaling,
with attendant targeting of speciﬁc regions for
each sex that depend upon maturational phases
of vulnerability of various neural cell popula-
tions (Garcia et al. 2002, 2003; Rodier 1988;
Slotkin 1999, in press a). Indeed, CPF affects
replication and differentiation of both neurons
and glia, thus eliciting neurotoxicant actions
over all the exposure periods studied here
(Aldridge et al. 2003; Garcia et al. 2002, 2003;
Icenogle et al., in press; Levin et al. 2001,
2002; Meyer et al. 2003; Qiao et al. 2003;
Raines et al. 2001; Slotkin 1999, in press a;
Slotkin et al. 2001a, 2002). Nevertheless,
because AC signaling is a common ﬁnal path-
way for the transduction of diverse neural and
hormonal signals involved in neural cell differ-
entiation, axonal outgrowth, synaptic plastic-
ity, and apoptosis (Bhat et al. 1983; Claycomb
1976; Guidotti 1972; Hultgårdh-Nilsson
et al. 1994; Shaywitz and Greenberg 1999;
Stachowiak et al. 2003; Van Wijk et al. 1973),
lasting disruption of this pathway by CPF is
likely to contribute directly to neurobehavioral
Article | Meyer et al.
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Figure 3. Effects of GD17–20 CPF exposure on PN60 AC activity in (A) hippocampus, (B) striatum, (C) mid-
brain, and (D) cerebellum. Abbreviations: Fsk, forskolin; Iso, isoproterenol; Rx, treatment. Data are means
and SEs of the percent change from corresponding control values (Table 1). ANOVA results for each
region across all variables are as follows: for (A) Rx, p < 0.05; for (B) Rx × measure, p < 0.02;
Rx × sex × measure, p < 0.1; for (C) Rx × sex, p < 0.1; for (D) Rx × sex, p < 0.07; subdivision into the two
sexes was carried out only when the ANOVA indicated an interaction of treatment × sex. Lower-order
tests are shown within the ﬁgure. 
*Individual groups differ significantly from the control (calculated only when lower-order tests indicated a significant
treatment × measure interaction).
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Figure 4. Effects of PN1–4 CPF exposure (1 mg/kg/day) on PN60 AC activity in (A) the cerebral cortex and
brainstem, and (B) the cerebellum. Abbreviations: Fsk, forskolin; Iso, isoproterenol; Rx, treatment. Data are
means and SEs of the percent change from corresponding control values (Table 1). ANOVA results across
all variables are as follows for (B): Rx × sex, p < 0.09; Rx × measure, p < 0.0004; Rx × sex × measure,
p < 0.007). For each region, ANOVA is shown across all variables, with subdivision into the two sexes car-
ried out only when the ANOVA indicated an interaction of treatment × sex. Lower-order tests are shown
within the ﬁgure. 
*Individual groups differ significantly from the control (calculated only when lower-order tests indicated a significant
treatment × measure interaction).
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Mn2+anomalies (Icenogle et al., in press; Levin et al.
2001, 2002). Furthermore, the fact that alter-
ations in AC signaling are heterologous, rather
than being conﬁned to the immediate cholin-
ergic target of CPF’s actions, implies that
effects will be exerted in regions, such as the
cerebellum, that are sparse in cholinergic pro-
jections, and that alterations will extend to
other neurotransmitter pathways. Again, this
corresponds to earlier observations of disrupted
cell replication and differentiation and synaptic
communication in disparate brain regions
(Aldridge et al. 2003; Campbell et al. 1997;
Dam et al. 1999a; Garcia et al. 2003; Meyer
et al. 2003; Raines et al. 2001; Slotkin 1999;
Slotkin et al. 2002; Whitney et al. 1995).
There were four major features of the last-
ing alterations of AC signaling elicited by
developmental exposure to CPF: regional selec-
tivity, existence of a peak period of sensitivity,
localization of the effects to speciﬁc signaling
proteins, and preferential effects according to
sex. First, the regional targeting changed dra-
matically with a shift in the CPF exposure
period but not in a manner that would be pre-
dicted solely from the maturational timetable
of each region. In general, neural maturation
occurs earliest in the brainstem, later in fore-
brain areas, and last in the cerebellum (Rodier
1988). In contrast to that pattern, we found
effects of CPF on AC signaling components in
both early- and late-developing regions with
either gestational or postnatal exposures, and
without a distinct ontogenetic shift as would
be expected from uniform targeting of a spe-
ciﬁc phase of cell development. Again, this is
consistent with CPF’s ability to affect different
neural cell types by a variety of mechanisms
ranging from mitotic inhibition to impairment
of differentiation, axonogenesis, and synapto-
genesis (Barone et al. 2000; Pope 1999; Rice
and Barone 2000; Slotkin 1999, in press a).
Nevertheless, our results point to a specific
phase in which CPF is most likely to disrupt
long-term programming of AC function. With
the earliest exposure (GD9–12), effects were
seen only when the dose was raised to 5 mg/kg,
above the threshold for systemic toxicity as
assessed by impaired maternal weight gain
(Qiao et al. 2002); even then, the magnitude
of effect was only half of that seen with CPF
exposure in later periods. With later gestational
exposure (GD17–20), significant sex-depen-
dent effects on AC signaling began to emerge
at subtoxic exposure, best exempliﬁed by the
female cerebellum. Shifting the treatment to
the postnatal period intensified the effects,
with significant alterations in multiple brain
regions at 1 mg/kg in animals treated on
PN1–4, a dose that causes no discernible sys-
temic toxicity (Dam et al. 1999a, 2000; Song
et al. 1997); similarly, treatment with 5 mg/kg
on PN11–14 elicited robust long-term alter-
ations in AC signaling in adulthood. It thus
appears that the early neonatal period in the
rat, which approximates neurologic develop-
ment in the third trimester and perinatal stage
of human brain development (Rodier 1988), is
particularly sensitive to persistent effects on AC
signaling. Interestingly, this is the same conclu-
sion that was reached from evaluations of the
short-term effects on AC signaling in the fetal
and neonatal brain seen immediately after CPF
treatment (Meyer et al. 2003; Song et al.
1997), suggesting that the persistent effects are
dependent on the earlier changes. Given the
role of cAMP in neural development, it seems
likely that there is a mechanistic link between
early perturbations and the persistent alter-
ations seen here in adulthood.
CPF exposure evoked alterations in AC
signaling at all loci within the pathway, dis-
playing both temporal and regional selectivity
for the targeting of speciﬁc proteins. With the
earliest treatment (GD9–12), the responses to
the two direct AC stimulants forskolin and
Mn2+ were enhanced to the same extent, sug-
gesting augmented expression and/or catalytic
activity of AC itself. Because there was no
change in the forskolin:Mn2+ response ratio,
it is unlikely that there was a shift in the AC
isoform, so a global increase in AC expression
is probable. A similar effect was seen in the
female hippocampus and male striatum after
CPF exposure on GD17–20 and in the cerebral
cortex after PN1–4 treatment. On the other
hand, the PN11–14 treatment did produce a
change in the forskolin:Mn2+ response ratio
across multiple brain regions in females, indi-
cating that isoform shifts can also be elicited,
speciﬁcally with late postnatal exposure. Effects
on the isoproterenol response, both in absolute
terms and relative to the changes in the
forskolin response, also indicated the targeting
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Figure 5. Effects of PN11–14 CPF exposure
(5 mg/kg/day) on PN60 βAR binding. Abbreviations:
Bs, brainstem; Cb, cerebellum; Cx, cerebral cortex;
Hp, hippocampus; Mb, midbrain; Rx, treatment; St,
striatum. Data are means and SEs of the percent
change from corresponding control values
(Table 1). Across all treatments, all regions, and
both sexes, ANOVA (Rx, p < 0.03; Rx × sex, p < 0.03)
indicated a signiﬁcant treatment effect that differed
between the two sexes, so values were separated
to conduct lower-order ANOVAs for males and
females. Individual regions for which the CPF group
differs from the control were not tested because of
the absence of a treatment × region interaction.
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Figure 6. Effects of PN11–14 CPF exposure (5 mg/kg/day) on PN60 AC activity. (A) Males. (B) Females. (C) AC activity ratios. Abbreviations: Bs, brainstem; Cb,
cerebellum; Cx, cerebral cortex; Fsk, forskolin; Hp, hippocampus; Iso, isoproterenol; Mb, midbrain; Rx, treatment; St, striatum. Across all regions and both sexes,
ANOVA indicated a signiﬁcant interaction of treatment with sex, so values were separated for males (A) and females (B). Data are means and SEs of the percent
change from corresponding control values (Table 1). ANOVA across all regions and measures is as follows: for (A) Rx × measure, p < 0.02; for B, Rx, p < 0.04;
Rx × measure, p < 0.02). Lower-order tests of the individual AC measures are shown within the figure. Separate tests for each region were not carried out
because of the absence of a treatment × region interaction. Activity ratios (C) were calculated because of the selective effects of CPF on the various AC stimulants;
ANOVA across regions appears within the ﬁgure.
*Individual groups differ signiﬁcantly from the control (calculated only when lower-order tests indicated a signiﬁcant treatment × region interaction).
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*of receptor-mediated AC stimulation. With
GD9–12 treatment, the βAR-mediated effect
was augmented to a smaller extent than that of
the direct AC stimulant (decreased isopro-
terenol:forskolin response ratio), suggesting an
impairment of receptor coupling to AC super-
imposed on the induction of AC itself. The
same effect was seen in the striatum when
CPF treatment was given on GD17–20, in the
cerebral cortex and male cerebellum with the
PN1–4 exposure, and in the male striatum
and cerebellum for the PN11–14 exposure.
We also found one instance of a specific
enhancement of the isoproterenol response, in
the brainstem of the PN1–4 group. Again, it is
possible to make inferences about the actual
locus of CPF’s effects on βAR-mediated AC
signaling: none of the changes correlated with
the alterations in βAR binding sites, which in
some cases were opposite to the effects on the
isoproterenol AC response. Accordingly, these
particular effects of CPF are likely to depend
upon alterations in expression or function of
the G-proteins that couple βARs to AC activ-
ity. Our general conclusion, then, is that the
effects of CPF on AC signaling reﬂect actions
exerted at the levels of the signaling compo-
nents downstream from the receptors, the
G-proteins and AC itself; therefore, the
changes are heterologous, affecting all inputs
that converge on this pathway. This inference
is consistent with the view that development
of G-protein–coupled receptor-mediated cell
signaling is regulated primarily by mechanisms
operating at the levels of G-proteins and AC
(Gao et al. 1998, 1999; Gaudin et al. 1995;
Karoor et al. 1996; Kohout and Lefkowitz
2003; Ostrom et al. 2000; Slotkin et al. 2003;
Vatner et al. 1998; Watts 2002).
Finally, as in our previous studies with
CPF (Aldridge et al. 2003; Dam et al. 2000;
Garcia et al. 2002; Icenogle et al., in press;
Levin et al. 2001, 2002; Slotkin et al. 2001a,
2002), we found distinct sex differences for
exposures on GD17–20, PN1–4, or PN11–14
but not with the early gestational treatment
(GD9–12). As examples, with the GD17–20
regimen, βAR binding was affected in oppo-
site directions in males and females, as were
striatal and cerebellar AC activities; for PN1–4
exposure, basal and isoproterenol-stimulated
AC activities were reduced in males but
enhanced in females; and for the PN11–14
treatment, βARs and forskolin-stimulated AC
were reduced only in females, the isopro-
terenol:forskolin response ratio was affected in
opposite directions in the two sexes, and only
females showed an AC isoform shift (reduced
forskolin:Mn2+ response ratio). Although it is
not possible from these data alone to deter-
mine a speciﬁc mechanism for the sex differ-
ences, it is important to note that sexual
differentiation of the brain commences
toward the latter part of gestation in the rat
(McCarthy 1994; Mong and McCarthy 1999)
and specifically involves the cAMP pathway
(Auger 2003). Although CPF is only weakly
estrogenic (Andersen et al. 2002; Vinggaard
et al. 2000), there is new evidence that it inter-
feres with testosterone catabolism (Usmani
et al. 2003). Additionally, the effects of CPF
on brain development are themselves likely to
inﬂuence sexual differentiation and resultant
endocrine responses or hormonal levels
because CPF intoxication in adults has distinct
endocrine effects (Guven et al. 1999). In any
case, the present ﬁndings of a critical develop-
mental period for the lasting, sex-selective
effects of CPF on AC signaling are consonant
with behavioral assessments that demonstrate
the same window of vulnerability (Icenogle
et al., in press; Levin et al. 2001, 2002).
In summary, we found lasting alterations
in AC signaling in a wide variety of rat brain
regions after CPF exposure during develop-
mental windows ranging from the earliest
phases of brain development (neurulation)
through postnatal stages that are comparable
with human brain development in the perina-
tal period (Rodier 1988). Within this broad
window of vulnerability, there were differences
in the regional locus, sex selectivity, and the
specific signaling proteins targeted by CPF
that depended on the period of exposure.
Given the pivotal role played by AC signaling
as a ﬁnal common pathway in the response to
neuronal and hormonal signals, the persistent
alterations seen here are likely to contribute to
lasting physiologic and behavioral alterations
after developmental exposure to CPF.
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